FDA Grants Priority Review to Encorafenib/Cetuximab Combo for BRAF+ mCRC

The FDA has granted a priority review designation to a supplemental new drug application for the combination of encorafenib and cetuximab as a treatment for patients with advanced BRAF V600E­–mutant metastatic colorectal cancer following up to 2 prior lines of therapy.

Read the full article here

Related Articles